Valeant Sheds Staff, Creates Executive Panel After Bausch & Lomb Deal
This article was originally published in The Tan Sheet
The fast-growing, Canadian specialty pharma will shed more than 2,700 jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.
You may also be interested in...
Bausch + Lomb retains its name and becomes a division of Valeant in the $8.7 billion acquisition expected to close in the 2013 third quarter.
The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.
A deal that would combine two smaller specialty pharmas into one will result in a company with four main business areas.